We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Here are our new price targets.
Supernus Pharmaceuticals and Exelixis Inc. have the cash to be able to take some chances in order to improve their business prospects.
Let's check out the charts of ABT.
You'll want to avoid this one.
This stock will be a winner, but the short-term technical picture may require scaling in patiently.
The shares are only trading at 17 times forward earnings, and might not be fully valued just yet.
Let's review the charts and indicators.
Here's what to avoid.
The charts of the vaccine maker indicate it's a good time to take some profits or raise stops, or both.